Drug search by name

Niraparib Tosylate and Pancytopenia

Result of checking the interaction of drug Niraparib Tosylate and disease Pancytopenia for safety when used together.

Check result:

Niraparib Tosylate <> Pancytopenia

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Hematologic adverse reactions (thrombocytopenia, anemia and neutropenia) have been reported in patients treated with niraparib. It is recommended to monitor complete blood counts weekly for the first month, monthly for the next eleven months of treatment, and periodically after this time. Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (less than equal to Grade 1). If hematological toxicities do not resolve within 28 days following interruption, discontinue niraparib, and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics.

Niraparib Tosylate

Generic Name: niraparib

Brand Name: Zejula

Synonyms: Niraparib

What is Niraparib Tosylate?